TY  - CHAP
M1  - Book, Section
TI  - Inflammatory Bowel Disease
A1  - McQuaid, Kenneth R.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
Y1  - 2022
N1  - 
T2  - Current Medical Diagnosis & Treatment 2022
AB  - KEY  CLINICAL  UPDATES  IN  INFLAMMATORY  BOWEL  DISEASEFor  patients  who  require  more  than  one  course  of  corticosteroid  therapy  every  1–2  years  for  symptomatic  relapse,  treatment  should  be  ‘stepped  up’  to  include  a  thiopurine  (azathioprine  or  mercaptopurine)  or  a  biologic  agent.A  2020  American  Gastroenterological  Association  guideline  recommends  either  infliximab  or  vedolizumab  as  first-line  therapies  for  moderate  to  severe  colitis  based  on  their  efficacy  and  safety  profiles.These  two  agents  had  the  highest  rankings  of  all  biologic  agents  for  induction  of  clinical  remission  in  a  2020  network  meta-analysis.Although  infliximab  may  be  the  more  effective  agent  (especially  for  severe  disease),  vedolizumab  may  be  the  preferred  first-line  therapy  in  patients  who  are  elderly  or  have  increased  medical  comorbidities  due  to  its  significantly  lower  incidence  of  infectious  complications.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184170657
ER  -